Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05271409 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
A Phase 3 study of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT05271409: Recruiting Phase 3 study of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), sponsored by Hoffmann-La Roche.
NCT05271409 is a Phase 3 study of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 152 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05271409, a Phase 3 study of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period. Participants who experience an adjudicated relapse or complete the DB period can enter open-label extension (OLE) period. After the primary clinical cutoff date (CCOD), additional adolescent participants may be enrolled directly into the OLE period.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Satralizumab
Study Locations (20)
Ohio
- University of Cincinnati - Cincinnati
- Cleveland Clinic Foundation - Cleveland
- OhioHealth Research Institute - Columbus
Florida
- University of Florida College of Medicine Gainesville - Gainesville
- Nemours Children's Clinic - of the Nemours Foundation - Jacksonville
Illinois
- Northwestern University - Chicago
- Consultants in Neurology Ltd - Northbrook
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic- Scottsdale - Scottsdale
California
- University of California Irvine - Manchester Pavilion - Irvine
Colorado
- University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center) - Aurora
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 3 |
What NCT05271409 shows while recruiting
NCT05271409 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05271409 names 20 study sites across 16 states, led by Ohio, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05271409 about?
NCT05271409 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease". The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period. Participants who experience an adjudicated relapse or complete the DB...
What is the current status of trial NCT05271409?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2022-08-30. Estimated completion is 2028-12-31.
What conditions does trial NCT05271409 study?
This clinical trial studies the following conditions: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).
What interventions are being tested in trial NCT05271409?
The interventions under investigation include: Placebo (OTHER), Satralizumab (DRUG).
Who is sponsoring clinical trial NCT05271409?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05271409 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05271409's enrollment target sits among peer trials
152 1514th of 2000 higher than 484 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI